DUBLIN, Calif., May 19 /PRNewswire-FirstCall/ -- SuperGen, Inc. today announced that it will webcast its Analyst & Investor Day live via the internet on Thursday, May 25, 2006 at 9:00 am EDT.
SuperGen’s management will provide a general corporate update and a detailed look at the expanded drug discovery capabilities and assets gained as a result of the acquisition of Montigen Pharmaceuticals, Inc. The program will include a scientific review of several kinase inhibitors now in development and an overview of the CLIMB(TM) discovery process.
The live webcast, including the slide presentation, will be available in the Investor Relations section of the Company’s website at http://www.supergen.com . This event webcast will be archived for 90 days.
About SuperGen
Based in Dublin, California, SuperGen is a pharmaceutical company dedicated to the discovery, acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. SuperGen’s portfolio includes Orathecin(TM) (rubitecan) capsules, an investigational drug intended for the treatment of pancreatic cancer, Nipent(R) (pentostatin for injection), Mitomycin, and Surface Safe(R) cleaner. In addition, a number of aurora-A, tyrosine kinase and DNA methyltransferase inhibitors are under development. For more information about SuperGen, please visit http://www.supergen.com .
Contacts: SuperGen Noonan Russo Timothy L. Enns Sharon Weinstein S.V.P., Corporate Communications Director of Investor Relations & Business Development Tel: (212) 845-4271 Tel: (925) 560-0100 x111 E-mail: sharon.weinstein@eurorscg.com E-mail: tenns@supergen.com
SuperGen, Inc.
CONTACT: Timothy L. Enns of SuperGen, S.V.P., Corporate Communications &Business Development, +1-925-560-0100 x111, tenns@supergen.com; SharonWeinstein of Noonan Russo, Director of Investor Relations, +1-212-845-4271,sharon.weinstein@eurorscg.com, for SuperGen
Web site: http://www.supergen.com/
